Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evidence lags behind excitement over blood plasma as a coronavirus treatment

Researchers call for more rigorous clinical trials as rumours abound that US regulators are considering widening access to the potential therapy.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

Update 24 August: The US Food and Drug Administration issued an emergency-use authorization on 23 August to treat COVID-19 with convalescent plasma.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 584, 505 (2020)

doi: https://doi.org/10.1038/d41586-020-02324-2

Updates & Corrections

  • Update 24 August 2020: The US Food and Drug Administration issued an emergency-use authorization on 23 August to treat COVID-19 with convalescent plasma.

References

  1. Joyner, M. J. et al. J. Clin. Invest. https://doi.org/10.1172/JCI140200 (2020).

    Article  Google Scholar 

  2. Joyner, M. J. et al. Preprint at medRxiv https://doi.org/10.1101/2020.08.12.20169359 (2020).

  3. Joyner, M. J. et al. Preprint at medRxiv https://doi.org/10.1101/2020.07.29.20162917 (2020).

  4. Landray, M. J. et al. Preprint at medRxiv https://doi.org/10.1101/2020.07.15.20151852 (2020).

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links